The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 2) (OPAL-Aim 2)
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Sep 6, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The OPAL-East Africa study is looking into how a short counseling session about alcohol use can help people who drink heavily and are at high risk for HIV. The goal is to see if this counseling can improve the use of preventive medications called PrEP and PEP, which can help protect against HIV. Researchers will also gather information on what helps or hinders people from sticking to these medications and how cost-effective this approach is.
To participate in this study, you need to be an adult (18 years or older), not currently infected with HIV, and have a certain level of alcohol use as determined by a screening test. You should also be planning to start a form of HIV prevention treatment and have access to a mobile phone. If you join, you can expect to receive support and guidance on how to manage your alcohol use and stay on track with your HIV prevention methods. The study is currently recruiting participants, and it’s a great opportunity to contribute to important research while receiving helpful resources.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥18 years)
- • HIV-uninfected (by rapid HIV antibody test)
- • AUDIT-C score of \>=4 for men and \>=3 for women
- • Attending a clinical visit for initiation of biomedical HIV prevention with oral or injectable PrEP or oral PEP (or the dapivirine vaginal ring, if available)
- • Has access to a mobile phone
- Exclusion Criteria:
- • Ineligible for PrEP based on MoH guidelines
- • Intention to move away from the study community in the coming year
- • Gross inebriation or inability to provide informed consent
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mbita, , Kenya
Mbarara, , Uganda
Patients applied
Trial Officials
Gabriel Chamie, MD, MPH
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported